{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.6","upperLimit":"65.6","value":"56.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"description":"Lymph node response (LNR) was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the product of the perpendicular diameters (SPD) of measurable index lesions as assessed by the study IRC.","dispersionType":"95% Confidence Interval","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"OG000","title":"Idelalisib"}],"paramType":"NUMBER","populationDescription":"Participants in the ITT Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Start of Treatment to End of Treatment (up to 81 months)","title":"Lymph Node Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}